ImmuneOnco Completes Phase III Enrollment for Timdarpacept in CMML Treatment

Reuters01-21

ImmuneOnco Completes Phase III Enrollment for Timdarpacept in CMML Treatment

ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd. announced the successful completion of enrollment of 104 patients in the Phase III clinical trial of IMM01 (Timdarpacept) for the first-line treatment of chronic myelomonocytic leukemia (CMML) as of December 31, 2025. The company expects to complete enrollment of the 132 patients required for interim analysis by the end of March 2026. Results from the trial have not yet been presented. IMM01 (Timdarpacept) in combination with azacitidine received orphan-drug designation from the U.S. Food and Drug Administration in November 2023. The company holds global intellectual property and commercial rights to IMM01 (Timdarpacept).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260121-11997345), on January 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605105702?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-21 19:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605105702","market":"nz","top_or_hot":-1,"title":"ImmuneOnco Completes Phase III Enrollment for Timdarpacept in CMML Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmuneOnco Completes Phase III Enrollment for Timdarpacept in CMML Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd. announced the successful completion of enrollment of 104 patients in the Phase III clinical trial of IMM01 (Timdarpacept) for the first-line treatment of chronic myelomonocytic leukemia (CMML) as of December 31, 2025. The company expects to complete enrollment of the 132 patients required for interim analysis by the end of March 2026. Results from the trial have not yet been presented. IMM01 (Timdarpacept) in combination with azacitidine received orphan-drug designation from the U.S. Food and Drug Administration in November 2023. The company holds global intellectual property and commercial rights to IMM01 (Timdarpacept).\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260121-11997345), on January 21, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmuneOnco Completes Phase III Enrollment for Timdarpacept in CMML Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmuneOnco Completes Phase III Enrollment for Timdarpacept in CMML Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-21 19:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmuneOnco Completes Phase III Enrollment for Timdarpacept in CMML Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd. announced the successful completion of enrollment of 104 patients in the Phase III clinical trial of IMM01 (Timdarpacept) for the first-line treatment of chronic myelomonocytic leukemia (CMML) as of December 31, 2025. The company expects to complete enrollment of the 132 patients required for interim analysis by the end of March 2026. Results from the trial have not yet been presented. IMM01 (Timdarpacept) in combination with azacitidine received orphan-drug designation from the U.S. Food and Drug Administration in November 2023. The company holds global intellectual property and commercial rights to IMM01 (Timdarpacept).\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260121-11997345), on January 21, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01541","symbol_name":"宜明昂科-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL5fs9KQ:1","article_id":"2605105702","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605105702","pubTimestamp":1768993579,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ImmuneOnco Biopharmaceuticals  Co. Ltd. announced the successful completion of enrollment of 104 patients in the Phase III clinical trial of IMM01  for the first-line treatment of chronic myelomonocytic leukemia  as of December 31, 2025. The company expects to complete enrollment of the 132 patients required for interim analysis by the end of March 2026. Results from the trial have not yet been presented. IMM01  in combination with azacitidine received orphan-drug designation from the U.S. Food and Drug Administration in November 2023. The company holds global intellectual property and commercial rights to IMM01 .Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals  Co. Ltd. published the original content used ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01541":"宜明昂科-B","BK1161":"生物科技"},"translate_title":"ImmuneOnco完成Timdarpacept治疗CMML的III期入组","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":0.9},"content_text":"ImmuneOnco Completes Phase III Enrollment for Timdarpacept in CMML Treatment\n    \n\n        ImmuneOnco Biopharmaceuticals (Shanghai) Co. Ltd. announced the successful completion of enrollment of 104 patients in the Phase III clinical trial of IMM01 (Timdarpacept) for the first-line treatment of chronic myelomonocytic leukemia (CMML) as of December 31, 2025. The company expects to complete enrollment of the 132 patients required for interim analysis by the end of March 2026. Results from the trial have not yet been presented. IMM01 (Timdarpacept) in combination with azacitidine received orphan-drug designation from the U.S. Food and Drug Administration in November 2023. The company holds global intellectual property and commercial rights to IMM01 (Timdarpacept).\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260121-11997345), on January 21, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605105702","isCrawlerRequest":true}